Interní Med. 2007; 9(12): 555-557

Progression of chronic kidney disease

doc. MUDr. Vladimír Tesař DrSc
I. interní klinika 1. LF UK a VFN Praha

Chronic kidney disease frequently progresses to end-stage renal failure even after the stabilization of the underlying renal disease. Mechanism of the progression still remains not completely elucidated. Except from glomerular hypertension both tubular and interstitial damage due to proteinuria and direct damage to the podocytes were suggested as potential culprits. Progression of chronic renal failure can be slowed down by the optimal control of the blood pressure and by the administration of angiotensin enzyme inhibitors and angiotensin antagonists. Experimental studies suggest that even regression of glomerulosclerosis and improvement of the renal function may be achieved, e. g. by the administration of BMP-7 or HGF.

Keywords: renal failure, progression, regression, glomerular hyperfiltration, glomerulosclerosis, interstitial fibrosis, proteinuria, podocytes

Published: January 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesař V. Progression of chronic kidney disease. Interní Med. 2007;9(12):555-557.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abbate M, Remuzzi G. Proteinuria as a mediator of tubulointerstitial injury. Kidney Blood Press Res., 1999; 22: 37-46. Go to original source... Go to PubMed...
    2. Adamczak M, Gross ML, Krtil J, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J. Am. Soc. Nephrol., 2003; 14: 2833-2842. Go to original source... Go to PubMed...
    3. Anderson S, Rennke HG, Garcia, DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int., 1989; 36: 525-536. Go to original source... Go to PubMed...
    4. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med., 1982; 307: 652-659. Go to original source... Go to PubMed...
    5. Fine LG, Ong AC, Norman JT. Mechanisms of tubulo-interstitial injury in progressive renal diseases. Eur. J. Clin. Invest.,1993; 23: 259-265. Go to original source... Go to PubMed...
    6. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med., 1998; 339: 69-75. Go to original source... Go to PubMed...
    7. Fogo AB. Progression versus regression of chronic kidney disease. Nephrol. Dial. Transplant., 2006; 21: 281-284. Go to original source... Go to PubMed...
    8. Iwano M, Neilson EG. Mechanism of tubulointerstitial fibrosis. Curr. Opin. Nephrol. Hypertens. 2004; 13: 279-284. Go to original source... Go to PubMed...
    9. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int., 2003; 63: 1874-1880. Go to original source... Go to PubMed...
    10. Kriz W, Elger M, Hosser H, et al. How does podocyte damage result in tubular damage? Kidney Blood Press Res, 1999; 22: 26-36. Go to original source... Go to PubMed...
    11. Kriz W. Progression of chronic renal failure in focal segmental glomerulosclerosis: consequence of podocyte damage or of tubulointerstitial fibrosis? Pediatr. Nephrol., 2003; 18: 617-622. Go to original source... Go to PubMed...
    12. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med., 1993; 329: 1456-1462. Go to original source... Go to PubMed...
    13. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanism of action. Am. J. Physiol. Renal Physiol., 2004; 287: F7-F16. Go to original source... Go to PubMed...
    14. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med.,1996; 334: 939-945. Go to original source... Go to PubMed...
    15. Matsuda H, Fukuda N, Ueno T, et al. Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-?1 promoter for treatment of progressive renal diseases. J. Am. Soc. Nephrol. 2006; 17: 422-432. Go to original source... Go to PubMed...
    16. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand. J. Clin. Lab. Invest., 1976; 36: 383-388. Go to original source... Go to PubMed...
    17. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet, 2003; 361: 117-124. Go to original source... Go to PubMed...
    18. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet, 2001; 357: 1601-1608. Go to original source... Go to PubMed...
    19. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005; 68: 2829-2836. Go to original source... Go to PubMed...
    20. Song JH, Cha SH, Lee HJ, et al. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-? in type 2 diabetic patients with advanced kidney disease. Nephrol. Dial. Transplant., 2006; 21: 683-689. Go to original source... Go to PubMed...
    21. Tonelli M, Moye L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J. Am. Soc. Nephrol., 2003; 14: 1605-1613. Go to original source... Go to PubMed...
    22. Yanagita M. Modulator of bone morphogenetic protein activity in the progression of kidney diseases. Kidney Int. 2006; 70: 989-993. Go to original source... Go to PubMed...
    23. Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM. Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int. 2004; 92 (Supl.): S76-S89. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.